ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1MRNA | MODERNA INC | Healthcare | $93.61B | 23.07% |
2ONC | BEONE MEDICINES LTD | Healthcare | $47.50B | 11.71% |
3RPRX | ROYALTY PHARMA PLC | Healthcare | $39.56B | 9.75% |
4ROIV | ROIVANT SCIENCES LTD | Healthcare | $28.98B | 7.14% |
5WST | WEST PHARMACEUTICAL SERVICES INC | Healthcare | $28.65B | 7.06% |
6GKOS | GLAUKOS CORP | Healthcare | $14.56B | 3.59% |
7PCVX | VAXCYTE INC | Healthcare | $10.24B | 2.52% |
8PTGX | PROTAGONIST THERAPEUTICS INC | Healthcare | $8.77B | 2.16% |
9ALKS | ALKERMES PLC | Healthcare | $7.89B | 1.95% |
10IMVT | IMMUNOVANT INC | Healthcare | $7.25B | 1.79% |
11LNTH | LANTHEUS HOLDINGS INC | Healthcare | $6.62B | 1.63% |
12LGND | LIGAND PHARMACEUTICALS INC | Healthcare | $6.33B | 1.56% |
13TFX | TELEFLEX INC | Healthcare | $6.07B | 1.50% |
14ERAS | ERASCA INC | Healthcare | $5.52B | 1.36% |
15PTCT | PTC THERAPEUTICS INC | Healthcare | $5.29B | 1.30% |
16SRRK | SCHOLAR ROCK HOLDING CORP | Healthcare | $5.27B | 1.30% |
17TNGX | TANGO THERAPEUTICS INC | Healthcare | $4.21B | 1.04% |
18RLAY | RELAY THERAPEUTICS INC | Healthcare | $3.99B | 0.98% |
19ABCL | ABCELLERA BIOLOGICS INC | Healthcare | $3.80B | 0.94% |
20IRON | DISC MEDICINE INC | Healthcare | $3.79B | 0.93% |
21ELVN | ENLIVEN THERAPEUTICS INC | Healthcare | $3.56B | 0.88% |
22ACHC | ACADIA HEALTHCARE COMPANY INC | Healthcare | $3.52B | 0.87% |
23ARQT | ARCUTIS BIOTHERAPEUTICS INC | Healthcare | $3.48B | 0.86% |
24DYN | DYNE THERAPEUTICS INC | Healthcare | $3.19B | 0.79% |
25DNLI | DENALI THERAPEUTICS INC | Healthcare | $3.03B | 0.75% |
26ADMA | ADMA BIOLOGICS INC | Healthcare | $2.94B | 0.72% |
27VCEL | VERICEL CORP | Healthcare | $2.93B | 0.72% |
28RCUS | ARCUS BIOSCIENCES INC | Healthcare | $2.56B | 0.63% |
29NEOG | NEOGEN CORP | Healthcare | $2.44B | 0.60% |
30REPL | REPLIMUNE GROUP INC | Healthcare | $2.08B | 0.51% |
31VIR | VIR BIOTECHNOLOGY INC | Healthcare | $2.08B | 0.51% |
32MRVI | MARAVAI LIFESCIENCES HOLDINGS INC | Healthcare | $2.00B | 0.49% |
33HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.98B | 0.49% |
34MAZE | MAZE THERAPEUTICS INC | Healthcare | $1.97B | 0.49% |
35ZBIO | ZENAS BIOPHARMA INC | Healthcare | $1.87B | 0.46% |
36ETON | ETON PHARMACEUTICALS INC | Healthcare | $1.77B | 0.44% |
37SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.72B | 0.42% |
38RAPP | RAPPORT THERAPEUTICS INC | Healthcare | $1.53B | 0.38% |
39PCRX | PACIRA BIOSCIENCES INC | Healthcare | $1.46B | 0.36% |
40ANAB | ANAPTYSBIO INC | Healthcare | $1.43B | 0.35% |
41INVA | INNOVIVA INC | Healthcare | $1.35B | 0.33% |
42STAA | STAAR SURGICAL CO | Healthcare | $1.34B | 0.33% |
43URGN | UROGEN PHARMA LTD | Healthcare | $1.29B | 0.32% |
44INBX | INHIBRX BIOSCIENCES INC | Healthcare | $1.29B | 0.32% |
45NKTR | NEKTAR THERAPEUTICS | Healthcare | $1.27B | 0.31% |
46MLTX | MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | $1.10B | 0.27% |
47IRMD | IRADIMED CORP | Healthcare | $1.09B | 0.27% |
48CBLL | CERIBELL INC | Healthcare | $1.02B | 0.25% |
49JBIO | JADE BIOSCIENCES INC | Healthcare | $1.01B | 0.25% |
50ALMS | ALUMIS INC | Healthcare | $793M | 0.20% |
51DSGN | DESIGN THERAPEUTICS INC | Healthcare | $678M | 0.17% |
52FDMT | 4D MOLECULAR THERAPEUTICS INC | Healthcare | $669M | 0.16% |
53DNA | GINKGO BIOWORKS HOLDINGS INC | Healthcare | $663M | 0.16% |
54CGEM | CULLINAN THERAPEUTICS INC | Healthcare | $662M | 0.16% |
55SGHT | SIGHT SCIENCES INC | Healthcare | $611M | 0.15% |
56NRC | NRC HEALTH | Healthcare | $565M | 0.14% |
57RCEL | AVITA MEDICAL INC | Healthcare | $509M | 0.13% |
58PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $418M | 0.10% |
59MASS | 908 DEVICES INC | Healthcare | $407M | 0.10% |
60PEPG | PEPGEN INC | Healthcare | $349M | 0.09% |
61ENTA | ENANTA PHARMACEUTICALS INC | Healthcare | $326M | 0.08% |
62EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $303M | 0.07% |
63SMTI | SANARA MEDTECH INC | Healthcare | $299M | 0.07% |
64FTH | FAETH THERAPEUTICS INC | Healthcare | $275M | 0.07% |
65ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $243M | 0.06% |
66DTIL | PRECISION BIOSCIENCES INC | Healthcare | $225M | 0.06% |
67TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $202M | 0.05% |
68KROS | KEROS THERAPEUTICS INC | Healthcare | $198M | 0.05% |
69KRRO | KORRO BIO INC | Healthcare | $196M | 0.05% |
70RNAC | CARTESIAN THERAPEUTICS INC | Healthcare | $194M | 0.05% |
71STRO | SUTRO BIOPHARMA INC | Healthcare | $159M | 0.04% |
72INGN | INOGEN INC | Healthcare | $146M | 0.04% |
73CUE | CUE BIOPHARMA INC | Healthcare | $127M | 0.03% |
74NTRB | NUTRIBAND INC | Healthcare | $73M | 0.02% |
75GOSS | GOSSAMER BIO INC | Healthcare | $69M | 0.02% |
76COCH | ENVOY MEDICAL INC | Healthcare | $53M | 0.01% |
77YARW | YARROW BIOSCIENCE INC | Healthcare | $52M | 0.01% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $405.68B. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 89% toward Large, 75% toward Growth. +5% unclassified (12 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 77 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T032403 rates=20261113T032429
Measured on the 2026-11 formation date across 77 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 31.2% | 26.4% |
| 3 yearsp.a. | 22.6% | -4.1% |
| 5 yearsp.a. | 7.6% | 4.1% |
| 10 yearsp.a. | 11.3% | 1.5% |
| Since inceptionp.a. | 12.2% | 5.3% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 39.9% | 31.2% |
| 2025 | 25.2% | -15.7% |
| 2024 | -14.6% | -33.8% |
| 2023 | 13.0% | 23.5% |
| 2022 | -20.6% | 9.9% |
| 2021 | -12.5% | 0.9% |
| 2020 | 81.9% | 19.5% |
| 2019 | 26.3% | 12.8% |
| 2018 | -21.2% | -17.5% |
| 2017 | 41.0% | 4.7% |
| 2016 | -7.0% | -19.4% |
| 2015 | 5.7% | 0.1% |
| 2014 | 30.5% | 10.8% |
| 2013 | 64.1% | 1.5% |
| 2012 | 11.9% | -17.5% |
| 2011 | 12.6% | -5.7% |
| 2010 | 2.9% | -13.6% |
| 2009 | 21.3% | -7.1% |
| 2008 | -24.2% | 22.5% |
| 2007 | 5.9% | -6.6% |
| 2006 | -2.8% | 0.2% |
| 2005 | 13.1% | -8.4% |
| 2004 | 10.9% | 12.3% |
| 2003 | 43.7% | 15.6% |
| 2002 | -16.7% | 44.5% |
| 2001 | 7.5% | 29.6% |
| 2000 | 35.4% | 20.2% |
| 1999 | 48.3% | 109.3% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare Investment Discipline Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Investment Discipline signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.